About Bluebird Bio
Bluebird Bio is a company based in Cambridge (United States) founded in 1992 was acquired by The Carlyle Group in February 2025.. Bluebird Bio has raised $210.68 million across 11 funding rounds from investors including ABN AMRO, The Carlyle Group and RA Capital. Bluebird Bio has completed 1 acquisition, including Pregenen. Bluebird Bio offers products and services including Gene Therapy for Sickle Cell Disease, Gene Therapy for Beta-Thalassemia, and Gene Therapy for Cerebral Adrenoleukodystrophy. Bluebird Bio operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BridgeBio, BeiGene and Advanced Accelerator Applications, among others.
- Headquarter Cambridge, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Bluebird Bio, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$210.68 M (USD)
in 11 rounds
-
Latest Funding Round
-
Investors
ABN AMRO
& 11 more
-
Employee Count
Employee Count
- Investments & Acquisitions
-
Acquired by
The Carlyle Group
(Feb 21, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Bluebird Bio
Bluebird Bio offers a comprehensive portfolio of products and services, including Gene Therapy for Sickle Cell Disease, Gene Therapy for Beta-Thalassemia, and Gene Therapy for Cerebral Adrenoleukodystrophy. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
FDA-approved one-time therapy to treat sickle cell disease genetically.
Treatment using lentiviral vectors for beta-thalassemia genetic disorder.
Gene-based approach to address cerebral adrenoleukodystrophy symptoms.
Unlock access to complete
Unlock access to complete
Leadership Team
42 people
Software Development Team
26 people
Senior Team
12 people
Sales and Marketing
6 people
Operations Team
5 people
Data Analysis and Operations Team
3 people
Product Management Team
3 people
QC Team
2 people
Unlock access to complete
Funding Insights of Bluebird Bio
Bluebird Bio has successfully raised a total of $210.68M across 11 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 11
- Last Round Last Round
-
First Round
First Round
(04 Oct 2004)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2022 | Amount | Post-IPO - Bluebird Bio | Valuation |
investors |
|
| Sep, 2021 | Amount | Post-IPO - Bluebird Bio | Valuation |
investors |
|
| Oct, 2012 | Amount | Grant - Bluebird Bio | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Bluebird Bio
Bluebird Bio has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include ABN AMRO, The Carlyle Group and RA Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Venture capital funding is provided to early-stage life science companies.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on life science companies
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Bluebird Bio
Bluebird Bio has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Pregenen. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Limited information available
|
2006 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Bluebird Bio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Bluebird Bio Comparisons
Competitors of Bluebird Bio
Bluebird Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BridgeBio, BeiGene and Advanced Accelerator Applications, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Bluebird Bio
Frequently Asked Questions about Bluebird Bio
When was Bluebird Bio founded?
Bluebird Bio was founded in 1992 and raised its 1st funding round 12 years after it was founded.
Where is Bluebird Bio located?
Bluebird Bio is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Is Bluebird Bio a funded company?
Bluebird Bio is a funded company, having raised a total of $210.68M across 11 funding rounds to date. The company's 1st funding round was a Grant of $9.3M, raised on Oct 04, 2004.
What does Bluebird Bio do?
Bluebird Bio was founded in 1992 in Cambridge, United States, within the biotechnology sector. Gene therapies are developed by the company for severe genetic diseases and rare conditions, including Lenti-D for childhood cerebral adrenoleukodystrophy and LentiGlobin for rare hemoglobinopathies. Preclinical programs are pursued for multiple myeloma and HPV-associated cancers. Homing endonuclease and megaTAL gene-editing technologies are applied in hematology and oncology areas.
Who are the top competitors of Bluebird Bio?
Bluebird Bio's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does Bluebird Bio offer?
Bluebird Bio offers Gene Therapy for Sickle Cell Disease, Gene Therapy for Beta-Thalassemia, and Gene Therapy for Cerebral Adrenoleukodystrophy.
How many acquisitions has Bluebird Bio made?
Bluebird Bio has made 1 acquisition, including Pregenen.
Who are Bluebird Bio's investors?
Bluebird Bio has 12 investors. Key investors include ABN AMRO, The Carlyle Group, RA Capital, Arch Venture Partners, and Tang Capital Partners.